Provided by Tiger Trade Technology Pte. Ltd.

Therapeutics

4.68
+0.02000.43%
Post-market: 4.680.00000.00%19:38 EDT
Volume:475.31K
Turnover:2.24M
Market Cap:146.44M
PE:-1.13
High:4.81
Open:4.71
Low:4.67
Close:4.66
52wk High:50.40
52wk Low:4.54
Shares:31.29M
Float Shares:18.39M
Volume Ratio:0.74
T/O Rate:2.58%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.1300
EPS(LYR):-2.8503
ROE:-59.21%
ROA:-37.36%
PB:0.67
PE(LYR):-1.64

Loading ...

Silexion Therapeutics Q2 EPS $(5.17) Misses $(2.12) Estimate

Benzinga Earnings
·
Aug 14

Trevi Therapeutics is Maintained at Buy by Jones Trading

Dow Jones
·
Aug 14

Oppenheimer Adjusts Pelthos Therapeutics PT to $64 From $66, Maintains Outperform Rating

MT Newswires Live
·
Aug 14

Press Release: Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update

Dow Jones
·
Aug 14

Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign

GlobeNewswire
·
Aug 14

Outlook Therapeutics Q3 Adj. EPS $(0.09), Inline, Sales $9.000K Miss $5.300M Estimate

Benzinga Earnings
·
Aug 14

Outlook Therapeutics Q3 Net Loss Narrows Slightly as Costs Drop

Reuters
·
Aug 14

Medicenna Therapeutics Q1 EPS $(0.06), Inline

Benzinga Earnings
·
Aug 14

Rein Therapeutics Q2 EPS $(0.10) Beats $(0.17) Estimate

Benzinga Earnings
·
Aug 14

Eledon Therapeutics: Buy Rating Reaffirmed on Strong Cash Runway and Tegoprubart Data; Price Target Unchanged at $8

TIPRANKS
·
Aug 14

HighTide Therapeutics Sets Board Meeting to Approve Interim Results

TIPRANKS
·
Aug 14

TenNor Therapeutics Sets Board Meeting to Review Interim Results and Possible Dividend

TIPRANKS
·
Aug 14

Outlook Therapeutics Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Benzinga Earnings
·
Aug 14

Percheron Therapeutics Adds New Shares to ASX Quotation

TIPRANKS
·
Aug 14

Modalis Therapeutics Issues Further Corrections to Interim Financial Results

TIPRANKS
·
Aug 14

PYC Therapeutics boosts CEO equity incentives with major option and rights grants

TIPRANKS
·
Aug 14

Silexion Therapeutics Executes Reverse Share Split Amid Strain

TIPRANKS
·
Aug 14

Tempest Therapeutics Secures Flexible $50 Million Equity Facility

TIPRANKS
·
Aug 14

Silexion Therapeutics Closes Public Offering and Strengthens Equity

TIPRANKS
·
Aug 14

Serina Therapeutics Q2 EPS $(0.55) Misses $(0.47) Estimate, Sales $130.000K, Same YoY

Benzinga Earnings
·
Aug 14